Svein Lien appointed ceo of Biotec Pharmacon

Lien has a financial background and extensive experience at technology and diagnostics businesses

Svein Lien has become chief executive of Norwegian pharmaceutical firm Biotec Pharmacon following the resignation of Lars Viksmoen.

Lien has a financial background and extensive experience at technology and diagnostics businesses, most recently as chief executive of Axis-Shield, a diagnostic company listed in London and Oslo.

Following divestment of Immunocorp Animal Health in 2008 and Immunocorp Consumer Health at the end of 2009 Biotec Pharmacon has narrowed its strategic focus to two core business areas: pharmaceutical development and marine biochemicals.

Pharmaceutical development is in the research and development phase, while Biotec Marine Biochemicals specialises in cold-adapted marine enzymes for the molecular biology and diagnostics markets.

You may also like

Ingredients

ArcticZymes receives research grant of US$1.3m

To develop new enzymes for research and diagnostics
Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs
Research & Development

OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial

OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss

Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Regulatory

Johnson & Johnson files FDA application for IMAAVY in wAIHA

Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
Research & Development

Almirall advances etherna’s mRNA/LNP therapy LAD116 into IND-enabling studies

Almirall has selected LAD116, developed using etherna's intratumoral mRNA/LNP platform, for IND-enabling studies in non-melanoma skin cancer, marking a key milestone toward GMP manufacturing and Phase I clinical trials
Subscribe now